
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>The San Diego Consensus for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}
</style>




</style>
</head>
<body>
<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>The San Diego Consensus for Laryngopharyngeal Symptoms and Laryngopharyngeal Reflux Disease</strong></summary>
            <div>
                <ul><li>This article presents the San Diego Consensus for Laryngopharyngeal Symptoms (LPS) and Laryngopharyngeal Reflux Disease (LPRD).</li><li>It aims to establish a modern, interdisciplinary care paradigm for evaluating and managing these conditions.</li><li>The consensus was developed by an international panel of experts from gastroenterology, otolaryngology, speech-language pathology, and clinical psychology.</li></ul>
                
        <details>
            <summary><strong>Background</strong></summary>
            <div>
                <ul><li>Laryngopharyngeal reflux (LPR) is a term often used for aerodigestive symptoms without objective reflux evidence.</li><li>This leads to diagnostic uncertainty and prolonged, often unsuccessful, treatments.</li><li>The initiative aims to create evidence-based recommendations for LPS evaluation and management.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Methods</strong></summary>
            <div>
                <ul><li>A 28-member international, inter-disciplinary working group was formed.</li><li>The group included gastroenterologists, laryngologists, speech-language pathologists, and a clinical psychologist.</li><li>The RAND Appropriateness Method (RAM) was used to determine the appropriateness of statements, with ≥80% agreement required for recommendations.</li></ul>
                
        <details>
            <summary><strong>Working Group Meetings</strong></summary>
            <div>
                <ul><li>The initiative spanned one year (October 2023 to October 2024).</li><li>Comprised seven working group meetings: five virtual and two hybrid with in-person meetings in Hong Kong (May 2024) and Austria (October 2024).</li><li>Several rounds of independent voting and sub-group meetings were conducted.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sub-groups</strong></summary>
            <div>
                <ul><li>14 members were assigned to sub-groups.</li><li>These sub-groups focused on: Definition &amp; Terminology, Initial Diagnostic Evaluation, Reflux Monitoring, Therapeutic Trial, Behavioral Factors &amp; Therapy, and Risk Stratification.</li><li>Each sub-group was led by two interdisciplinary co-chairs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>RAND Appropriateness Method (RAM)</strong></summary>
            <div>
                <ul><li>A validated methodology was utilized for determining the appropriateness of statements.</li><li>This method included independent electronic voting to determine the appropriateness of each statement.</li><li>Statements ranked as appropriate with ≥80% agreement were included as final recommendations.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Definition &amp; Terminology</strong></summary>
            <div>
                <ul><li>Laryngopharyngeal Symptoms (LPS) are defined as chronic and frequent throat and upper airway symptoms potentially induced by retrograde flow of gastric content.</li><li>LPS includes cough, voice hoarseness/change, throat clearing, excess phlegm, and throat pain/sore throat.</li><li>Laryngopharyngeal Reflux Disease (LPRD) requires chronic troublesome LPS AND objective evidence supporting the relationship between symptoms and gastroesophageal reflux.</li></ul>
                
        <details>
            <summary><strong>Laryngopharyngeal Symptoms (LPS)</strong></summary>
            <div>
                <ul><li>Symptoms must be frequent, occurring at least twice weekly, and present for more than 8 weeks.</li><li>Commonly cited symptoms include cough (89%), regurgitation (89%), throat pain/sore throat (89%), throat clearing (86%), excess phlegm (82%), and hoarseness/voice change (80%).</li><li>Globus is an important symptom warranting further evaluation but did not reach agreement for inclusion as an LPS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laryngopharyngeal Reflux Disease (LPRD)</strong></summary>
            <div>
                <ul><li>The proportion of individuals found to have objective LPRD on diagnostic evaluation is low, approximately 35%.</li><li>Both LPS and objective evidence of gastro-esophageal reflux are needed for a diagnosis of LPRD.</li><li>Diagnostic evidence supporting the relationship between LPS and gastroesophageal reflux is required prior to invasive anti-reflux management.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Evaluation of LPS</strong></summary>
            <div>
                <ul><li>Laryngoscopy is a necessary part of evaluation of LPS to assess for other non-reflux related otolaryngologic processes including malignancy.</li><li>LPRD cannot be diagnosed based on laryngoscopy findings alone.</li><li>The presence of concurrent esophageal reflux symptoms versus absence, referred to as isolated LPS, should be determined.</li></ul>
                
        <details>
            <summary><strong>Role of Laryngoscopy</strong></summary>
            <div>
                <ul><li>Laryngoscopy is necessary to rule out alternate laryngeal pathologies including neoplasia.</li><li>Findings on laryngoscopy alone cannot diagnose LPRD.</li><li>Laryngoscopic findings such as infraglottic edema, interarytenoid mucosal hypertrophy, and post-cricoid mucosal edema are non-specific for LPRD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptom Characterization &amp; Role of Medical Trials</strong></summary>
            <div>
                <ul><li>The presence of concurrent esophageal reflux symptoms versus absence, referred to as isolated LPS, should be determined.</li><li>In patients with LPS &amp; esophageal reflux symptoms, a trial of medical anti-reflux management, along with dietary and lifestyle modification, is appropriate.</li><li>In patients with isolated LPS, esophageal evaluation is recommended instead of empiric medical trials.</li></ul>
                
        <details>
            <summary><strong>Medical Anti-Reflux Trial</strong></summary>
            <div>
                <ul><li>Includes twice daily PPI for 3 months with or without alginate therapy.</li><li>Alginate therapy taken four times daily (after meals and before bedtime) can decrease LPS.</li><li>In patients with isolated LPS, acid-reducing medications are not recommended as first-line therapy without diagnostic evidence of reflux.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Esophageal Evaluation</strong></summary>
            <div>
                <ul><li>Esophageal evaluation, including upper GI endoscopy and/or ambulatory reflux monitoring, is the next step in the investigation of LPS with typical esophageal symptoms when unresponsive to empiric treatment trials, and in isolated LPS.</li></ul>
                
        <details>
            <summary><strong>Upper GI Endoscopy</strong></summary>
            <div>
                <ul><li>Conclusive evidence of GERD on upper GI endoscopy includes Los Angeles grades B, C, D esophagitis and/or biopsy proven Barrett’s esophagus.</li><li>The presence of disrupted esophagogastric junction on endoscopy, such as hiatal hernia, may serve as adjunctive evidence for LPRD.</li><li>Office-based transnasal esophagoscopy (TNE) has been shown to be similarly diagnostic for Barrett’s esophagus and certain other esophageal pathologies compared to standard upper endoscopy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ambulatory Reflux Monitoring</strong></summary>
            <div>
                <ul><li>Ambulatory reflux monitoring is the reference standard for diagnosing LPRD.</li><li>LPRD diagnosis is required prior to invasive anti-reflux management.</li><li>In patients with isolated LPS, reflux testing can personalize management better than empiric treatment trials.</li></ul>
                
        <details>
            <summary><strong>Indications</strong></summary>
            <div>
                <ul><li>Diagnostic evaluation for LPRD should be considered if long-term medical anti-reflux management is recommended.</li><li>Evidence of abnormal reflux burden is essential prior to endoscopic or surgical antireflux interventions.</li><li>In the absence of endoscopic evidence of GERD, ambulatory reflux monitoring is the reference standard for diagnosing LPRD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Modality &amp; Interpretation of Ambulatory Reflux Monitoring</strong></summary>
            <div>
                <ul><li>Ambulatory reflux monitoring for evaluation of LPRD in patients with unproven GERD should be performed off acid suppression therapy.</li><li>pH-impedance and wireless pH monitoring measure different properties of LPRD and are not mutually exclusive.</li><li>Distal esophageal acid exposure time (AET) greater than 6.0% on ambulatory reflux monitoring meets criteria for proven GERD.</li></ul>
                
        <details>
            <summary><strong>pH-Impedance Monitoring</strong></summary>
            <div>
                <ul><li>A diagnostic option for LPRD, particularly in patients with isolated laryngopharyngeal symptoms.</li><li>Offers the ability to detect proximal reflux events with greater detail.</li><li>Hypopharyngeal reflux events were demonstrated using dual channel or hypopharyngeal-esophageal multichannel intraluminal impedance with dual pH (HEMII-pH) catheters.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Prolonged Wireless pH Testing</strong></summary>
            <div>
                <ul><li>A diagnostic option for LPRD, particularly in patients with concomitant esophageal reflux symptoms and prior to escalation of reflux management.</li><li>AET less than 4.0% on all four days of 96-hour wireless pH monitoring predicts low likelihood of symptom response with anti-secretory therapy.</li><li>Prolonged pH monitoring also provides a higher diagnostic yield of pathologic GERD in patients with LPS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Oropharyngeal pH Testing</strong></summary>
            <div>
                <ul><li>Oropharyngeal pH monitoring alone has poor specificity for LPRD in patients with laryngopharyngeal symptoms.</li><li>This technique is not specific, cannot detect weakly-acidic or non-acidic reflux, has poor concordance with traditional pH-impedance monitoring, and does not correlate with clinical outcomes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Laryngeal Hyperresponse and Hypervigilance</strong></summary>
            <div>
                <ul><li>Hyperresponsive laryngeal behaviors, with or without true LPRD, may contribute to or be the primary etiology of LPS.</li><li>Laryngeal symptom-specific anxiety and hypervigilance may contribute to or be the primary etiology of LPS.</li><li>The Laryngeal Cognitive Affective Tool can help identify individuals with symptom-specific anxiety and hypervigilance.</li></ul>
                
        <details>
            <summary><strong>Laryngeal Behavioral Factors</strong></summary>
            <div>
                <ul><li>The larynx is a critical intersection of breathing, communication and swallowing.</li><li>Laryngeal hyperresponse can manifest as repetitive laryngeal behaviors such as throat clearing or coughing, breath-holding, or as biomechanical strain at the vocal folds.</li><li>Laryngeal hypervigilance, defined as increased threat-induced attention to the larynx, and symptom-specific anxiety, defined as fear/worry about LPS and perceived consequences, are psychological processes that can influence LPS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laryngeal Behavioral Therapy</strong></summary>
            <div>
                <ul><li>Individuals with LPS can undergo initial laryngeal recalibration therapy (LRT) provided by a voice-specialized speech-language pathologist.</li><li>LRT involves combined voice therapy techniques, autonomic regulation and cognitive reframing to address perceived and confirmed irritation manifesting as cough, throat-clearing, dyspnea and voice change.</li><li>Behavioral therapies used to address psychological targets, such as cognitive behavioral therapy, can be used alone or in combination with other modalities in patients with LPS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Neuromodulation</strong></summary>
            <div>
                <ul><li>Neuromodulators may improve laryngeal hypersensitivity. These include tricyclic antidepressants, as well as gabapentin and pregabalin (particularly studied in cough).</li><li>Pharmacologic neuromodulation may attenuate laryngeal hypersensitivity and may be considered in LPRD patients with suboptimal response to anti-secretory therapy or SLP intervention and in isolated LPS with negative esophageal testing.</li><li>Tricyclic antidepressants, commonly prescribed for the treatment of functional GI disorders, should be used with caution because of anticholinergic effects which may cause dry mouth and aggravate LPS.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>PRO Instruments &amp; Risk Stratification Tools</strong></summary>
            <div>
                <ul><li>Common PRO instruments for GERD (GERDQ, GERD-HRQL) are valuable in assessing the severity and treatment response of esophageal symptoms, but have suboptimal diagnostic yield for LPS and LPRD.</li><li>Currently available LPRD-specific PRO instruments should not be used to diagnose LPRD due to insufficient specificity.</li><li>Some clinical risk stratification tools (HAS-BEER, COuGH RefluX) were developed in recent years to help direct initial diagnostic and management strategies in patients with LPS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion</strong></summary>
            <div>
                <ul><li>The San Diego Consensus for LPS &amp; LPRD (SD-LPRD) is a modern-day evidence-based paradigm for evaluation and management of LPS.</li><li>The physiological mechanisms underlying “LPR” are often unclear and can be neurogenic, inflammatory, behavioral or motility related.</li><li>A major distinction is between presenting symptoms pertaining to the upper aerodigestive tract, termed LPS, from confirmed reflux-mediated pathophysiology based on objective findings, termed LPRD.</li></ul>
                
        <details>
            <summary><strong>Key Distinctions</strong></summary>
            <div>
                <ul><li>An expert evaluation of the larynx using laryngoscopy ± stroboscopy is an important step in evaluating any patient with LPS, not only to document findings, but also to rule out non-reflux etiologies for LPS.</li><li>The presence of typical esophageal symptoms should be assessed as evaluation and management algorithms differ for isolated LPS and concurrent LPS with esophageal reflux symptoms.</li><li>Prior to initiating anti-reflux therapy in isolated LPS, or when empiric treatment trials fail in LPS associated with esophageal symptoms, further esophageal evaluation includes upper GI endoscopy and ambulatory reflux monitoring.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ambulatory Reflux Monitoring</strong></summary>
            <div>
                <ul><li>In planning ambulatory reflux monitoring, the diagnostic evaluation of LPS potentially related to reflux may require the determination of whether symptoms arise from a reflux mediated mechanism or a reflex mechanism.</li><li>pH-impedance monitoring, particularly using a HEMII-pH or dual pH impedance catheter, can distinguish between these mechanisms and provide definitive evidence of reflux events.</li><li>Prolonged wireless reflux monitoring provides precise information regarding the presence or absence of pathologic acid burden.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laryngeal Hyperresponsiveness and Hypervigilance</strong></summary>
            <div>
                <ul><li>In the case of isolated LPS or when LPS fail to respond to anti-reflux therapies even in confirmed LPRD, overlap with laryngeal hyperresponsiveness and hypervigilance should be considered, and behavioral therapy and/or neuromodulation recommended.</li><li>Laryngeal behavioral therapies offered through trained SLPs and other behavioral therapists can hold value in disorders with laryngeal hyperresponsiveness and hypervigilance independent of the underlying mechanism.</li><li>The LCAT holds potential to identify patients with LPS who could benefit from behavioral therapies and/or neuromodulation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>
</body>
</html>
